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Abstract
Background: Additional urinary biomarkers for diabetic nephropathy (DN) are needed, providing early and reliable
diagnosis and new insights into its mechanisms. Rigorous selection criteria and homogeneous study population
may improve reproducibility of the proteomic approach.
Methods: Long-term type 1 diabetes patients without metabolic comorbidities were included, 11 with sustained
microalbuminuria (MA) and 14 without MA (nMA). Morning urine proteins were precipitated and resolved by 2D
electrophoresis. Principal component analysis (PCA) and Projection to latent structures discriminatory analysis (PLS-DA)
were adopted to assess general data validity, to pick protein fractions for identification with mass spectrometry (MS),
and to test predictive value of the resulting model.
Results: Proteins (n = 113) detected in more than 90% patients were considered representative. Unsupervised PCA
showed excellent natural data clustering without outliers. Protein spots reaching Variable Importance in Projection
score above 1 in PLS (n = 42) were subjected to MS, yielding 33 positive identifications. The PLS model rebuilt with
these proteins achieved accurate classification of all patients (R2X = 0.553, R2Y = 0.953, Q2 = 0.947). Thus, multiple
earlier recognized biomarkers of DN were confirmed and several putative new biomarkers suggested. Among them,
the highest significance was met in kininogen-1. Its activation products detected in nMA patients exceeded by an
order of magnitude the amount found in MA patients.
Conclusions: Reducing metabolic complexity of the diseased and control groups by meticulous patients’ selection
allows to focus the biomarker search in DN. Suggested new biomarkers, particularly kininogen fragments, exhibit the
highest degree of correlation with MA and substantiate validation in larger and more varied cohorts.
Keywords: Diabetes, Nephropathy, Proteomics, Kallikrein-kinin system
Background
Diabetic nephropathy (DN) is a major complication of
diabetes mellitus (DM), largely responsible for the out-
break of dialysis-dependent end stage renal disease we
have witnessed during last few decades. It substantially
impairs quality of life in patients with diabetes and im-
poses a considerable burden of health-care costs [1].
Once developed, DN cannot be efficiently reversed;
hence successful management must be based on timely
selection of patients at risk and therefore indicated to
more stringent glycaemic control. A prerequisite of such
approach is availability of a non-invasive, highly sensitive
and specific screening tool [2]. Currently, this task is
usually achieved by regular measurement of urinary al-
bumin excretion. Nevertheless, microalbuminuria (MA)
is neither a specific nor an early marker and misdiag-
nosis or underestimation of evolving DN often under-
mines treatment outcomes [3]. Therefore, some authors
suggest leaving this concept completely [4]. So obviously
we need more precise criteria to define target popula-
tions which would benefit from the emerging strategies
for diabetes therapy.
Unlike MA, which roughly estimates glomerular per-
meability, new biomarkers promise to reflect more
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aspects of DN and hence to detect earlier stages with en-
hanced specificity [5]. Mass spectrometry-based (MS)
proteomics provides an unbiased and complex approach
to analysis of protein mixtures which seems optimal for
this task [6] and several attempts have been made to
define a specific urinary proteome in patients with DN
or even to discover more reliable biomarkers. However,
most of these studies have serious limitations and so far
no markers were introduced into clinical practice [7].
Apparently, such a goal cannot be reached by a single
study – first, potential biomarkers must be searched for
in limited, well defined groups of patients and conse-
quently validated on larger populations [6].
As validation trials are cost and time consuming, stud-
ies searching for new markers of DN must be carefully
designed and address several challenges: a study group
with maximum homogeneity and appropriate controls, a
preparation method covering wide range of molecular
weights and yielding enough material for identification,
and MS technology capable to describe both intact pro-
teins and fragments. Here we present a discovery-phase
trial based on these requirements.
Methods
Study design and patient population
This was a prospective, observational, controlled, single-
centre study. The study protocol was approved by Ethics
Committee for Multi-Centric Clinical Trials of the
University Hospital Motol (ref. No EK-1407/08); all sub-
jects signed an informed consent before enrolment in
the study. Patients were recruited at Motol University
Hospital (Prague, Czech Republic) outpatient clinic, pri-
marily through database search; the selection criteria
were subsequently validated on the screening visit.
The inclusion criteria were as follows: age >18 years,
ability to sign informed consent, type 1 DM confirmed
by C peptide with minimum duration of 15 years, BMI
<30 kg/m2, and at least 3 follow-ups including albumin
excretion test within last year. Exclusion criteria were as
follows: history of kidney disease (other than DN), esti-
mated glomerular filtration rate (eGFR) <60 ml/min/m2,
active infection, malignancy, liver disease, or cardiopul-
monary insufficiency.
Patients showing persistent microalbuminuria (defined
as 2.5-35 mg/mmol albumin/creatinine ratio or albumin-
uria 30–300 mg/24 h on at least 2 of 3 follow-ups) and
diabetic retinopathy were assigned to the study group
(MA). The control group (nMA) was compiled of pa-
tients suffering from type 1 DM for over 20 years and
showing no microalbuminuria (or retinopathy) on the
last three follow-ups (or previously) even without any
type of renin-angiotensin system blockade.
Totally, 32 patients were enrolled yet only 25 of them
were analysed – in 5 patients criteria of MA were not
met at the study visit and in two control subjects urine
samples did not yield enough protein for two-dimensional
electrophoresis (2-DE). Renin-angiotensin-aldosterone
system (RAAS) antagonists were discontinued per proto-
col one day before sample collection. The period of 24 h
has been chosen to ensure maximum reduction in the dir-
ect RAAS inhibition without wasting its long-term bene-
fits and inflicting structural damage.
Clinical and laboratory evaluation
Patients’ demographic and clinical characteristics in-
cluding medical history, current and past medication,
height, weight, and blood pressure were obtained by
interview, examination, and medical record review
on the day of the screening visit. The first morning
urine was collected for protein analysis. Blood and
urine samples were drawn and sent for routine la-
boratory analysis including serum creatinine, glycated
haemoglobin, and lipid levels, urinary creatinine and
albumin concentrations. eGFR was calculated using
CKD-EPI formula.
Urinary protein preparation
All chemicals used during preparation and analyses were
purchased from Sigma (Sigma-Aldrich, Steinheim,
Germany).
All urine samples were processed within 4 h after col-
lection. The mean processed sample volume was 156 ml
in MA patients and 246 ml in nMA patients. Mean pro-
tein concentration (determined with Bradford assay) was
320 mg/l (±103.2 mg/l) in MA group and 50.1 mg/l
(±6.7 mg/l) in nMA group. Each sample was first centri-
fuged for 15 min at 3780 g at 4 ° C to remove cells and
insoluble debris. Then, the supernatant was mixed with
60% trichloroacetic acid (ratio 5:1) and incubated over-
night in the ice cold water bath. On the next day, sam-
ples were centrifuged for 1 h at 3780 g at 4 °C. The
pellet was washed with 5–10 ml ice-cold acetone, incu-
bated 10 min in the ice-cold water bath, and then centri-
fuged for another hour. The final pellet was resuspended
in the lysis buffer (7 M urea, 2 M thiourea, 4% CHAPS,
2% IPG buffer pH 3–10, 120 mM DTT, 40 mM Tris
base) and stored frozen at −80 °C.
Two-dimensional electrophoresis
The method was described in detail previously [8].
Briefly, 200 μg proteins were applied onto 11 cm IPG
strips, rehydrated, and focused. The second-dimension
separation was performed on precast polyacrylamide
gels. Next, the gels were stained with Simply Blue and
the spots of interest excised using a spot-cutter.
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MALDI (matrix-assisted laser desorption/ionization) TOF
(time-of-flight) tandem MS and protein identification
The method was described in detail previously [8]. Briefly,
proteolytic peptides obtained by tryptic digestion of the
excised proteins were analyzed using a 4800 MALDI
TOF/TOF Analyzer (Applied Biosystems, Framingham,
MA, USA). Protein identification was achieved by search-
ing against the human subset of the SwissProt protein
database (Swiss Institute of Bioinformatics, Basel,
Switzerland) (release 2010_09; 10 Aug 2010) using the
MASCOT 2.1.0 search algorithm (Matrix Science,
London, UK).
2-DE pattern analysis, statistics, and data presentation
Computer aided analysis of 2-DE gel images was carried
out using PDQuest 2D software version 8.1 (Bio-Rad,
Hercules, CA, USA). A synthetic image was constructed
out of the triplicated or duplicated gels (as applicable
with respect to the amount of protein available) proc-
essed from each sample, using only spots constantly
present in at least two gels. The protein quantity was de-
termined relative to integrated spot density excluding
saturated spots.
The statistical analysis was carried out by means of
Statistica data analysis software (Version 8.0, Statsoft
Inc., Tulsa, OK, USA). Proteomic data are characterized
by high degree of collinearity, multiple variable interac-
tions, and variable numbers exceeding that of cases.
Under such conditions, the traditional univariate ap-
proach fails and multivariate techniques should be con-
sidered, which allow for inter-variable correlations and
reduce data dimensionality by extracting principal com-
ponents (latent variables). Among them, Principal Com-
ponent Analysis (PCA) is a method appropriate for
unsupervised data exploration while Projection to Latent
Structures – Discriminant Analysis (PLS-DA) can be
used to evaluate classification potential of the data set
to discriminate between predefined classes [9]. Vari-
able Importance in the Projection (VIP) score serves
to rank variables according to their significance in the
PLS-DA model.
In the current study, PCA based on covariance matrix
was applied to examine natural data clustering and to
screen for potential outliers. Only spots detectable in >
90% samples in any of the two groups were considered
eligible for PCA. PLS-DA models were built with a bin-
ary coded dummy response matrix; using 7-fold cross-
validation strategy to avoid over fitting. Protein spots
with regression coefficients for which the jack-knifed
95% confidence interval did not include 0 and VIP
scores exceeded 1 were selected for identification and
the model was re-calculated thereafter using these vari-
ables. Mann–Whitney rank sum test was employed to
compare group characteristics and as a confirmatory
tool for proteomic data. Differences were considered sta-
tistically significant if the p-values were < 0.01 for prote-
omic data and < 0.05 for other data types.
Results
Patients’ demographic and relevant clinical characteris-
tics are shown in Tab. 1. The two groups were
homogenous with respect to gender, age, DM duration,
BMI, blood pressure, and lipid profile. Not surprisingly,
patients with MA had higher glycated haemoglobin level
and slightly worse kidney function as indicated by serum
creatinine and eGFR. Clearly, urinary albumin/creatinine
ratio was markedly higher in the MA group.
Two-dimensional electrophoresis (2DE) of purified
urinary protein yielded a total of 755 protein fractions
(spots). Of this number, 100 spots were detected exclu-
sively in the MA group, 88 solely in the nMA group,
and 567 were documented in both. Individual gels (one
from each group) with most typical spot distribution, i.e.
containing most of the detected spots, are presented in
Fig. 1 and a magnified area in Fig. 2. Spots detected in
more than 90% gels in any group (n = 113) were arbitrar-
ily considered representative (of either group) and as
such included into the PCA. The projection of individual
cases on the factor plane is shown in Additional file 1.
The first principal component separated all patients into
two compact clusters leaving no obvious outliers. More-
over, these two naturally occurring clusters precisely
agreed with the study groups divided according to
microalbuminuria.
To directly test the performance of specific proteins in
assigning patients to the MA and nMA groups, PLS-DA
model was built on the 113 spot intensities. Variables
(n = 49) reaching VIP score > 1.0 were regarded to
have the highest discriminatory power and therefore
apt for further analysis (Additional file 2). During
manual review, 7 spots were sorted out for being ei-
ther inadequately resolved (e.g. overlapping with adja-
cent spots) or too faint to guarantee successful MS
identification. Remaining 42 spots were subjected to
MS/MS which was accomplished in 33 spots. Overall, 23
individual proteins were identified – their description as
well as differences in abundance between both groups are
given in Tab. 2. Both PLS-DA models (i.e. based on 113
and 33 variables) were capable to correctly classify all pa-
tients (positive as well as negative predictive value =
100%); detailed characteristics of the latter model are
shown in Fig. 3 (R2X = 0.553, R2Y = 0.953, Q2 = 0.947).
In most proteins, observed molecular weight (MW)
and pI were in good agreement with the theoretical
ones. However, in several cases the measured MW was
markedly lower than predicted by SwissProt database.
Here, the peptide size and amino acid sequence established
by MS/MS experiments were investigated thoroughly to
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show if they corresponded with any documented functional
domains or cleavage fragments. These included (spot No,
measured MW, calculated MW of the fragment/intact pro-
tein): kininogen-1 heavy chain (#1, MW 57, 41/70 kDa),
extracellular domain of secreted and transmembrane
protein 1 (# 16, 17, MW 18, 13/24 kDa), LG3 peptide
from basement membrane-specific heparan sulphate
proteoglycan core protein (# 11, 23, 21/467 kDa),
35 kDa chain of inter-alpha-trypsin inhibitor heavy
chain H4 (# 15, MW 35, 35/70 kDa) and C1q domain of
multimerin 2 (# 13, MW 18, 14/102 kDa); complete
sequences are presented in Additional file 3.
Discussion
To discover potential early biomarkers for diabetic ne-
phropathy, a group of type 1 diabetes patients in the ini-
tial phase of the renal disease and meeting the most
stringent criteria was put together, urine samples col-
lected, and isolated proteins resolved by 2-DE. Resulting
proteome map was compared with that of a control
group comprising type 1 diabetes patients without kid-
ney involvement and protein fractions best explaining
the between-group variation were identified by mass
spectrometry. Both the characteristic urinary prote-
ome (i.e. common to more than 90% patients) and its
representative subset provided an accurate classifica-
tion of all patients. Among the candidate biomarkers
most significantly contributing to the model, kinino-
gen fragments deserve a special attention as the
kallikrein-kinin pathway is considered to play a cen-
tral role in DN pathogenesis.
During the last decade, a considerable effort was spent
searching early urinary markers of DN, however the out-
comes lack congruity desirable to achieve before the val-
idation phase can be undertaken [7]. A great deal of the
inconsistency can be attributed to patients’ heterogen-
eity. From this perspective, the major strength of the
current study lies in the high degree of uniformity in
terms of metabolic and co-morbid conditions, a number
one prerequisite for a successful biomarker discovery.
Table 1 Study groups – demographic and clinical characteristics
microalbuminuric non-microalbuminuric p
Cases (male/female) 11 (6/5) 14 (6/8) 0.57
DM duration (years) 26 (20–30) 22.5 (21–25) 0.78
Age (years) 35 (33–44) 35 (32–40) 0.76
BMI (kg/m2) 25.35 (21.97–28.6) 24.15 (23.51–24.96) 0.41
Systolic BP (mmHg) 138 (118–154) 138 (124–143) 1
Diastolic BP (mmHg) 84 (77–88) 79.5 (74–90) 0.62
Serum creatinine (μmol/l) 87 (81–116) 71.5 (61–76) <0.01
eGFR (ml/min)a 77.8 (63.6–100.4) 108.8 (101.5–113.1) <0.01






Serum cholesterol (mmol/l) 4.6 (4.1–5.4) 5.4 (4.5–5.7) 0.13
Triglycerides (mmol/l) 1.21 (1.09–1.34) 0.88 (0.72–1.97) 0.38
Data are given as medians (IQR), statistical significance was confirmed with Mann–Whitney rank sum test
aeGFR was calculated by CKD-EPI formula
bIn 9 non-microalbuminuric patients, urinary albumin was under the detection limit (<3 mg/l), here the albumin concentration was set arbitrarily to 3 mg/l
Fig. 1 Representative gel images from individual patients with (a)
and without (b) microalbuminuria. Spot numbers correspond with
the list in Table 2
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Another significant advantage is the capability of
MALDI approach to identify proteins from a wide range
of molecular weights including fragments.
Urine has been shown to reflect many pathologic and
physiologic conditions with the highest accuracy and
sensitivity [5]. At the same time, diabetes is a profound
metabolic disorder presenting with a variety of organ in-
volvements and therefore maximum homogeneity in
terms of renal and extrarenal disease stage, comorbidi-
ties, and treatment should be sought. Unlike type 2 DM,
associated with insulin resistance and affecting metabol-
ism in virtually all tissues, type 1 DM in non-obese
adults, if adequately substituted with insulin, provides
the purest available form of DN [10]. In contrast, most
studies examined type 2 DM and only few were focused
on type 1 (two analysed less than 10 patients, i.e. 5 and
4) [7], while disease stage and comorbidities were rarely
addressed. Urine harbours a complex mixture of variably
sized, partially degraded peptides and proteins in aque-
ous phase - a hurdle, which can be overcome by means
of gel-based proteomics [11]. Unlike many previous
studies done with different technologies, we were able to
gather information on proteins’ identity, quantity and
fragmentation.
Inevitably, the study has limitations. The sample size is
small and diagnosis of DN on the basis of MA uncertain.
Moreover, low patient numbers make results vulnerable
to group misclassification arising from surrogate diagno-
sis [12]. These weaknesses are shared by most trials and
probably partly responsible for ambiguous outcomes.
However, molecular technologies do not permit analys-
ing large patient groups and kidney biopsy is neither
clinically relevant nor ethically justifiable “per protocol”.
To minimize the chance of error, selection criteria were
set to conform to the highest possible specificity. There-
fore only patients with diabetic retinopathy, suffering
from DM long enough to develop DN and showing
sustained microalbuminuria (without erythrocyturia or
overt proteinuria) were considered eligible. The major
disadvantage of gel-based approach, namely the labori-
ous procedure restricting numbers of proteins analysed,
was balanced by a careful selection of spots for identifi-
cation [9].
In the urine of MA patients, equally as many proteins
were found down-regulated as up-regulated. This result,
while in agreement with previous studies, seems coun-
terintuitive [7]. A possible explanation would be that
proteinuria reflects not only increased permeability of
glomeruli but also dysfunction of various physiological
systems. The proteins ranged in MW from 18 to
120 kDa and included many traditional biomarkers of
DN: albumin (multiple forms), transferrin, ceruloplas-
min, immunoglobulin kappa and lambda chains, α1-
microglobulin, or orosomucoid [13]. Intact albumin was
not included in the analysis as its quantification was
hampered by spot saturation; however several albumin
fragments were found up-regulated. Newly discovered
proteins are both intracellular and secreted, bearing both
enzymatic, signalling, and structural functions and cov-
ering all major pathways recognized in DN pathophysi-
ology, especially metabolic derangement, inflammation,
regulatory, and structural (vascular) alterations.
Although the exact function of the kallikrein-kinin sys-
tem in the pathogenesis of DN has not been fully eluci-
dated, it is considered to play a beneficial role, closely
cooperating with renin-angiotensin system [14]. Presum-
ably, it exerts its activity via nitric oxide synthesis, thus
affecting kidney haemodynamics, metabolism, inflamma-
tory processes, etc. Clinical experience has been recently
supported by mechanistic experiments showing protect-
ive effects of local kininogen expression on evolution of
microalbuminuria [15]. In the current study, the most
significant predictor of group assignment to MA group
was diminished urinary excretion of kininogen-1
heavy chain (i.e. cleavage fragment documenting prior
bradykinin release).
Fig. 2 Kininogen-1 in patients with (a) and without (b) microalbuminuria. Magnified areas of 2D gels from all patients show Kininogen-1 activation
product (heavy chain, spot #1), Alpha-1-acid glycoprotein 1 (spot #30), and Zinc-alpha-2-glycoprotein (spot #21)
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Kidney has been established as an important site of
glucose metabolism and increased oxidative stress due
to impaired glycolysis is considered the major culprit re-
sponsible for development of angiopathy and organ
complications [16–18]. Glycolytic flux is blocked up-
stream from glyceraldehyde-3-phosphate dehydrogenase
(G3P) which is supposed to play a central role in the
dysregulation. Subsequent diversion of glycolytic inter-
mediates into other pathways (polyol, hexosamine) leads
to excessive generation of reactive oxygen species.
Decreased excretion of G3P and enolase in the MA
group could reflect this condition, though both enzymes
exhibit also other effects such as cell cycle regulation,
apoptosis, and fibrinolysis.
DN has been further linked to low-grade inflammation
and activation of the complement system. Specifically,
mannan-binding lectin (MBL) levels correlate with the
progression of renal disease in type 1 DM [19]. MBL to-
gether with its associated protease (mannan-binding lec-
tin serine protease 2 - MASP2) initiates the complement
cascade [20] and, indeed, the activated form of MASP2
was increased in MA group. Glutaminyl-peptide cyclo-
transfrase (QPCT) is a secreted protein catalyzing for-
mation of N-terminal pyroglutamate, a post-translational
modification rendering the target peptides less degrad-
able. It has been shown an important factor affecting
macrophage infiltration [21] which is in turn hold re-
sponsible for tubular and mesangial inflammation during
early phase of DN [22]. Also the extracellular portion of
another protein, vesicular integral-membrane protein
VIP36, is involved in the regulation of macrophage
phagocytosis (and shedded during the process) [23].
Finally, secreted and transmembrane protein 1 (SCTM1)
is a T-cell co-stimulatory ligand produced by monocytes
and neutrophils [24].
LG3 peptide derived from perlecan (basement
membrane-specific heparin sulphate proteoglycan core
protein), a negatively charged proteoglycan and a major
constituent of glomerular basement membrane, was
found depleted in urine from the MA group. Although
its indispensability for the membrane’s selective properties
under physiological conditions has been challenged re-
cently [25], perlecan probably acts as a pathogenic factor
in diseased states [26]. Moreover, the LG3 fragment ex-
presses anti-angiogenic properties [27]. Inter-α-inhibitor
heavy chain 4 (ITIH4) is an acute phase reactant, yet its
function is largely unknown; the sequence covered by
MS/MS spanned within the kallikrein-generated 35 kDa
C-terminal fragment [28]. Its serum quantity has been
shown to correlate with various conditions including tu-
mours and diabetes [29]. Multimerin-2 is an endothelial
cell surface protein, proposed as an important inhibitor of
vasculogenesis interfering with vascular endothelial
growth factor A (VEGF) [30]. At the same time, complica-
tions of diabetes including nephropathy are inherently as-
sociated with VEGF-induced vascular remodelling and
dysregulated angiogenesis [31]. Phosphatidyl-ethanolamine-
binding protein 1 has been firmly linked with pathological
neovascularisation in cancer [32]. Its expression in
mesangial cells is promoted by high glucose [33], yet
Fig. 3 Partial least squares – discriminant analysis: final model
representing 33 protein fractions. panel a: scores plot (shows
supervised projection of all cases). panel b: loadings plot (shows
contribution of variables to classification, positive are surplus in
MA group and vice versa). panel c: validation plot (shows superiority of
suggested model over random models). R2X = 0.553, R2Y = 0.953, Q2 =
0.947. VIP = Variable Importance in Projection, MS =mass spectrometry
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its extracellular concentration was shown to decrease
in proliferative diabetic retinopathy [34].
At least in two cases the results suggest an association
of MA with decreased activity, local or systemic, of the
kallikrein system. While the role of kininogen-bradykinin
axis has been widely recognized, the significance of ITIH4
is uncertain. It may represent another pathogenic mech-
anism or simply reflect low activity of kallikrein proteases.
The relation of both pathways (as documented by urinary
levels of identical kininogen and ITIH4 fragments) to pro-
teinuria progression under treatment with ACE inhibitors
was described lately by Rocchetti et al. in patients suffer-
ing from IgA nephropathy [35]. So, rather than constitut-
ing a specific trait of DN, this finding could imply a
condition, inherent or acquired, rendering the kidney
more vulnerable to variable pathogenic stimuli (specula-
tively haemodynamic in nature) inducing proteinuria.
The initial enthusiasm associated with proteomic bio-
marker quest has been gradually reduced as every new
trial supplied more potential molecules yet very few ap-
plicable tests resulted. Given the diversity of mechanisms
involved in DN pathogenesis, it is probably unrealistic to
expect one parameter (or even a set of parameters) could
unequivocally confirm or rule out the disorder. Maybe we
should rather aim at characterizing the unique and time-
dependent interplay of metabolic, inflammatory, and re-
pair processes operating within a specific individual. Such
approach would necessitate detection of functional clus-
ters or pathways among discovered biomarkers and their
correlation with clinical and histological descriptors. On
the other hand, this kind of knowledge would be superior
as it could help to stratify or personalize the therapy.
Conclusion
Reducing metabolic complexity of the diseased and con-
trol groups by meticulous patient selection together with
appropriate statistical methodology allowed to focus the
biomarker search in DN. In this way, we generated a
compact set of potential new biomarkers exhibiting the
highest degree of correlation with MA and substantiat-
ing validation in larger and more varied cohorts. These
proteins could provide, upon proper validation, either
separately or in concert, more reliable, timely, and de-
tailed diagnosis of DN.
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